Pantoprazol Tetrafarma (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Tetrafarma, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults. GNH USA supplies Pantoprazol Tetrafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Pantoprazol Tetrafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is indicated for conditions that involve excess gastric acid secretion.

- Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Erosive esophagitis: accelerates mucosal healing and reduces further damage. - Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and prevents recurrence. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with gastrin‑producing tumors. - NSAID‑induced ulcer prophylaxis: reduces the risk of ulcer formation in patients requiring long‑term NSAID therapy.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: typically self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: increased gas. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Acute interstitial nephritis: kidney inflammation. - Liver enzyme elevation: signs of hepatic stress.

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

- Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate hepatic status: use with caution in moderate to severe liver disease. - Review concomitant medications: potential for reduced efficacy of drugs requiring acidic pH. - Monitor long‑term users: watch for bone density loss and magnesium deficiency. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole may affect the absorption or metabolism of several co‑administered drugs.

Major Interactions (Avoid): - Ketoconazole or itraconazole: markedly reduced antifungal absorption. - Atazanavir: decreased antiviral exposure, risking treatment failure. - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent monitoring. - Digoxin: slight increase in serum levels. - Methotrexate (high dose): reduced renal clearance, may need dose adjustment. - Iron supplements: decreased iron absorption, separate dosing times.